Indaptus Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
INDP$2.90-7.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Stockholders’ Equity
Unaudited Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
| Common stock · Additional paid in · Accumulated | |||||
|---|---|---|---|---|---|
| Shares* | Amount* | Capital* | deficit | Total | |
| Balance, January 1, 2024 | 300,037 | $3,000 | $57,490,654 | $(45,417,156) | $12,076,498 |
| Stock-based compensation | - | - | 774,691 | - | 774,691 |
| Issuance of shares of common stock, net of issuance costs | 4,920 | 49 | 315,998 | - | 316,047 |
| Net loss | - | - | - | (3,806,677) | (3,806,677) |
| Balance, March 31, 2024 | 304,957 | 3,049 | 58,581,343 | (49,223,833) | 9,360,559 |
| Stock-based compensation | - | - | 782,852 | - | 782,852 |
| Issuance of shares of common stock, net of issuance costs | 505 | 5 | 38,059 | - | 38,064 |
| Net loss | - | - | - | (4,015,267) | (4,015,267) |
| Balance, June 30, 2024 | 305,462 | 3,054 | 59,402,254 | (53,239,100) | 6,166,208 |
| Stock-based compensation | - | - | 444,184 | - | 444,184 |
| Issuance of shares of common stock and warrants, net of issuance costs | 58,708 | 587 | 2,461,383 | - | 2,461,970 |
| Net loss | - | - | - | (3,069,036) | (3,069,036) |
| Balance, September 30, 2024 | 364,170 | $3,641 | $62,307,821 | $(56,308,136) | $6,003,326 |
| Balance, January 1, 2025 | 428,799 | $4,288 | $64,379,770 | $(60,439,183) | $3,944,875 |
| Stock-based compensation | - | - | 240,891 | - | 240,891 |
| Issuance of shares of common stock and warrants, net of issuance costs (Note 6b) | 75,335 | 754 | 1,985,990 | - | 1,986,744 |
| Issuance of shares of common stock, net of issuance costs (Note 6c) | 57,328 | 573 | 1,159,078 | - | 1,159,651 |
| Issuance of commitment shares (Note 6c) | 10,927 | 109 | (109) | - | - |
| Net loss | - | - | - | (4,532,430) | (4,532,430) |
| Balance, March 31, 2025 | 572,389 | 5,724 | 67,765,620 | (64,971,613) | 2,799,731 |
| Issuance of shares of common stock, net of issuance costs (Note 6c) | 32,574 | 326 | 574,743 | - | 575,069 |
| Stock-based compensation | - | - | 180,763 | - | 180,763 |
| Net loss | - | - | - | (5,228,919) | (5,228,919) |
| Balance, June 30, 2025 | 604,963 | 6,050 | 68,521,126 | (70,200,532) | (1,673,356) |
| Issuance of common stock and warrants upon conversion of promissory notes, net of issuance costs (Note 7) | 501,566 | 5,016 | 6,854,625 | - | 6,859,641 |
| Exercise of pre-funded warrants | 15,391 | 154 | - | - | 154 |
| Issuance of shares of common stock, net of issuance costs (Note 6d) | 520,000 | 5,200 | 2,238,591 | - | 2,243,791 |
| Stock-based compensation | - | - | 150,614 | - | 150,614 |
| Net loss | - | - | - | (2,975,117) | (2,975,117) |
| Balance, September 30, 2025 | 1,641,920 | $16,420 | $77,764,956 | $(73,175,649) | $4,605,727 |
| * | Retroactively restated for one-for-twenty-eight share consolidation on June 27, 2025. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.